Addex (ADXN) Principal Accounting Officer Receives Option Grants

What Happened
Teyssedou Lenaic Nathanael, Principal Accounting Officer of Addex Therapeutics Ltd. (ADXN), underwent a series of derivative transactions on September 2, 2026 in which a total of 602,908 option-based awards were surrendered to the issuer and the same number of new option awards were granted. Each disposition and corresponding acquisition was reported at $0.00 (derivative transaction). Per the filing footnote, the Remuneration Committee repriced the options so the new exercise price is $0.032 (reported in USD after conversion); no cash changed hands in these reported transfers.

Key Details

• Transaction date: September 2, 2026 (reported on Form 4 filed Sept 4, 2026).
• Total disposed (old options): 602,908 shares (derivative).
• Total acquired (new grants): 602,908 shares (derivative).
• Reported transaction price for the dispositions/acquisitions: $0.00 (reflecting exchange of awards rather than a cash sale/purchase).
• New exercise price: $0.032 (USD), conversion from CHF using rate $1.2296 per CHF 1.00 (per footnote).
• Exemptions cited: transactions exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act.
• Shares owned after transaction: not stated in the Form 4.
• Filing timeliness: Form 4 filed Sept 4 for Sept 2 transactions; filing does not indicate lateness.

Context
These entries are derivative transactions (options/awards) showing the surrender of prior option awards and the grant of replacement awards at a repriced exercise level. This is an administrative adjustment implemented by the company’s Remuneration Committee and not an open-market buy or sale of the company’s common stock. Such repricings reset the exercise price for the affected options; they do not, by themselves, represent a cash purchase or sale of shares.